Matthew M. Abernathy

Revisiting the hERG safety margin after 20 years of routine hERG screening

Derek J. Leishman, Matthew M. Abernathy, Evan B. Wang · Journal of Pharmacological and Toxicological Methods · 2020 · 36 citations

Medicine, Gynecology, Oncology +10

Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19

Annie Delaunois, Matthew M. Abernathy, Warren D. Anderson et al. · Clinical and Translational Science · 2021 · 34 citations · Full text

Medicine, Cardiology, Pharmacology +17

Development of a long‐acting relaxin analogue, LY3540378, for treatment of chronic heart failure

Petra Verdino, Stacey L. Lee, Fariba N. Cooper et al. · British Journal of Pharmacology · 2023 · 27 citations · Full text

Medicine, Cardiology, Pharmacology +14

A Case of Successful Thromboelastographic Guided Resuscitation after Postpartum Hemorrhage and Cardiac Arrest

Maurice Hurwich, D. Zimmer, E. Guerra et al. · Journal of ExtraCorporeal Technology · 2016 · 16 citations · Full text

Medicine, Hematology, Hemostasis +13

A Proof-of-Concept Evaluation of JTPc and Tp-Tec as Proarrhythmia Biomarkers in Preclinical Species: A Retrospective Analysis by an HESI-Sponsored Consortium

Emmanuel Boulay, Matthew M. Abernathy, Ray W. Chui et al. · International Journal of Toxicology · 2018 · 15 citations · Full text

Medicine, Cardiology, Pharmacology +17